Drug Profile
Naronapride - Renexxion
Alternative Names: ATI-7505Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator ARYx Therapeutics
- Developer ARYx Therapeutics; Dr Falk Pharma; Renexxion
- Class Anti-inflammatories; Benzamides; Gastrokinetics; Laxatives; Quinuclidines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Constipation; Gastro-oesophageal reflux; Gastroparesis; Non-ulcer dyspepsia
- Discontinued Erosive oesophagitis
Most Recent Events
- 07 Feb 2024 Renexxion expands its licensing and collaboration agreement with Dr. Falk Pharma to develop and commercialise Naronapride for Gastro-oesophageal reflux in Greater Europe (including UK), Russia, Central Asian Republics, and certain Australasian countries
- 24 Jan 2024 Renexxion Ireland plans a phase IIb trial for Gastroesophageal reflux disease in USA in 2024
- 24 Jan 2024 Renexxion Ireland files an IND application with the US FDA in USA for Gastro-oesophageal reflux, prior to January 2024